|Table of Contents|

A multi-dimensional classification based on Orphanet database for rare diseases of cancer in China

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 06
Page:
1094-1097
Research Field:
Publishing date:

Info

Title:
A multi-dimensional classification based on Orphanet database for rare diseases of cancer in China
Author(s):
GUO Yani; LUO Min; QING Chen; LIU Bo; GUO Yunping
College of Pharnaceutial Science and Yunnan Key Laboratory of Pharmacology for Natural Products,Kunming Medical University,Yunnan Kunming 650500,China.
Keywords:
rare diseases; classification; neoplasms; Orphanet database
PACS:
R730
DOI:
10.3969/j.issn.1672-4992.2022.06.030
Abstract:
Objective:Orphanet database is used to screen and classify tumor diseases in the Orphanet catalogues of rare diseases in China,in order to promote the establishment of multi-dimensional classification methods and database for rare diseases.Methods:Rare tumor diseases were selected based on the classification method of the Orphanet database.The relevant literature was retrieved through the authoritative journal literature database,and the subject classification data was sorted out,and the clinical manifestations and symptoms of tumor diseases were analyzed.Results:A total of 24 rare tumor diseases were screened out,accounting for 15.38% of the list of rare diseases.According to the particularity of rare diseases,a classification method based on subject classification is proposed,which has strong applicability and operability.Conclusion:In view of the lack of accurate classification standards for rare diseases in China,this study classifies tumor rare diseases from multiple dimensions,which is helpful to improve the recognition ability of tumor rare diseases and promote the further classification research of rare diseases.

References:

［1］陈永法,伍琳.我国罕见病界定标准初探［J］.中国卫生政策研究,2014,7(10):16-20. CHEN YF,WU L.Preliminary study on Chinese standards for defining rare diseases［J］.Chinese Journal of Health Policy,2014,7(10):16-20.
［2］夏梅君,龚时薇.中国专家关注的罕见病和罕用药问题及政策建议的文献系统评价［J］.中国医院药学杂志,2017,37(17):1655-1660. XIA MJ,GONG SW.Problems and strategies of rare diseases and orphan drugs in China based on a systematic literature review［J］.Chinese Journal of Hospital Pharmacy,2017,37(17):1655-1660.
［3］曲艳吉,詹思延.罕见疾病患病率的流行病学研究方法［J］.中华儿科杂志,2015,53(4):309-312. QU YJ,ZHAN SY.Epidemiological methods for studying the prevalence of rare diseases［J］.Chinese Journal of Pediatrics,2015,53(4):309-312.
［4］GARCIA M,DOWNS J,RUSSELL A,et al.Impact of biobanks on research outcomes in rare diseases:a systematic review［J］.Orphanet J Rare Dis,2018,13(1):202.
［5］WHICHER D,PHILBIN S,ARONSON N.An overview of the impact of rare disease characteristics on research methodology［J］.Orphanet J Rare Dis,2018,13(1):14.
［6］徐昊鹏,朱翀,弓孟春,等.中国罕见病研究的现状与未来［J］.协和医学杂志,2018,9(01):5-9. XU HP,ZHU C,GONG MC,et al.Research of rare diseases in China:from the past to the future［J］.Medical Journal of Peking Union Medical College Hospital,2018,9(01):5-9.
［7］刘鑫,李建涛,张鹏霄,等.中国孤儿药现状及与国外对比分析研究［J］.中国药学杂志,2019,54(10):839-846. LIU X,LI JT,ZHANG PX,et al.current status of orphan drugs in China and comparative analysis with foreign countries［J］.Chin Pharm J,2019,54(10):839-846.
［8］谢冰洁,蒋立新,徐江平.罕见病的初分类研究［J］.生命科学仪器,2018,16(2):52-57,62. XIE BJ,JIANG LX,XU JP.The preliminary study of the rare disease classification［J］.Life Science Instruments,2018,16(2):52-57,62.
［9］郑帅,田国祥,韩迪迪,等.Orphanet数据库架构及数据获取方法与流程［J］.中国循证心血管医学杂志,2020,12(6):651-654. ZHENG S,TIAN GX,HAN DD,et al.Orphanet database architecture and data acquisition methods and processes［J］.Chin J Evid Based Cardiovasc Med,2020,12(6):651-654.
［10］杨艳华,贺建华.以腹痛为首发症状的原发性腹膜癌1例诊断分析并文献复习［J］.医学理论与实践,2019,32(02):255-256. YANG YH,HE JH.Diagnosis of one case of primary peritoneal carcinoma with abdominal pain as the first symptom and literature review［J］.J Med Theor ＆ Prac,2019,32(02):255-256.
［11］黄蓉飞,高立敏,修英杰,等.淋巴造血组织肿瘤构成的多原发肿瘤临床病理特征［J］.中华肿瘤防治杂志,2015,22(24):1906-1910. HUANG RF,GAO LM,XIU YJ,et al.Clinicopathologic al features of multiple primary malignant neoplasms constituted by tumors of hematopoietic and lymphoid tissues［J］.Chinese Journal of Cancer Prevention and Treatment,2015,22(24):1906-1910.
［12］林凤村,黄建丽,王尤佳.基于SEER数据库回顾性分析食管神经内分泌癌的放疗价值［J］.现代肿瘤医学,2020,28(20):3541-3545. LIN FC,HUANG JL,WANG YJ.A retrospective analysis of the value of radiotherapy in esophageal neuroendocrine carcinomas based on SEER database［J］.Modern Oncology,2020,28(20):3541-3545.
［13］苏江维,余慧,杜坤,等.CCL2和ETS-1在皮肤黑色素瘤组织中的表达及临床意义［J］.现代肿瘤医学,2021,29(11):1938-1942. SU JW,YU H,DU K,et al.Expressions and clinical significances of CCL2 and ETS-1 in cutaneous melanoma［J］.Modern Oncology,2021,29(11):1938-1942.
［14］KULKARNI A,CARLEY H.Advances in the recognition and management of hereditary cancer［J］.Br Med Bull,2016,120(1):123-138.
［15］刁其林,唐蓓,游梦,等.首诊于口腔医院的肢端肥大症1例［J］.临床口腔医学杂志,2020,36(07):431-433. DIAO QL,TANG B,YOU M,et al.A case of acromegaly first diagnosed in stomatological hospital［J］.Journal of Clinical Stomatology,2020,36(07):431-433.

Memo

Memo:
National Natural Science Foundation of China(No.81860463）；国家自然科学基金地区科学基金(编号：81860463)；云南省科技厅-昆明医科大学应用基础研究联合专项重点项目［编号：2018FE001(-003)］
Last Update: 1900-01-01